Clinical trial · Observational
The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
NCT02583659CI-TRIAL-00019765unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective cohort study aims to observe the efficacy and safety of the first-line combined chemotherapy for advanced gastric cancer(AGC) in Chinese population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Combined chemotherapy
- description
- AGC patients treated with first-line combined chemotherapy
Primary outcomes (1)
- measure
- Overall survival(OS) . overall survival Overall survival(OS)
- timeFrame
- From date of enrollment until the date of death from any cause, assessed up to 60 months
Secondary outcomes (4)
- measure
- Progression-free survival(PFS)
- timeFrame
- From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
- measure
- Objective response rate(ORR)
- timeFrame
- The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma; 2. Unresectable locally advanced, or recurrent, or metastasis disease； 3. Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed. 4. Life expectancy of at least 3 months; 5. ECOG score 0-2; 6. Voluntarily signed the informed consent. Exclusion criteria: 1. Previously treated with first-line chemotherapy; 2. First-line chemotherapy with single drug.
References
Publications (0)
Data not yet available
No reference posted for this study.